Cannabis flavonoids, collectively referred to as cannflavin, are gaining attention from Canadian scientists as a potential therapy to counter pain and inflammation. Flavonoids are important chemical compounds that lend fruits and vegetables their color, as well as antioxidant properties. The two types of Cannabis flavonoids that are of particular interest are cannflavin A and cannflavin B.
In the mid-1980s, Marilyn Barrett of the University of London was first to identify these agents, also making the discovery that they are 30 times more efficient in reducing pain and inflammation than aspirin. However, relief required large quantities of 'raw material than the Toronto Star described as "Cheech and/or Chong levels.”
Fast forward to August 2019, when researchers at the University of Guelph in Ontario developed a patented process that uses genome mining to target and isolate the specific genes in cannabis that create cannflavins, with which cannflavin A and B can be metabolically synthesized without having to grow the plant. The scientists credit this breakthrough to advances in genomics research and the legalization of marijuana in Canada.